{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:10:35Z","timestamp":1788844235768,"version":"build-2803163510"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aimed to systematically review model-based economic evaluations of next-generation sequencing for guiding targeted therapy in non-small cell lung cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Embase, the Cochrane Library, Web of Science, China National Knowledge Infrastructure, VIP Database, and Wanfang Database from inception to March 20, 2026, to identify economic evaluations of next-generation sequencing for molecular testing in non-small cell lung cancer. Two reviewers independently screened studies, extracted data, and assessed reporting quality using the Consolidated Health Economic Evaluation Reporting Standards 2022 checklist. A qualitative synthesis was conducted to summarize study characteristics, model structures, testing strategies, cost-effectiveness results, and sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighteen model-based economic evaluations were included. Seven modeling approaches were identified, among which hybrid models combining a decision tree with a partitioned survival model were most frequently used, followed by decision tree\u2013Markov models. Most studies evaluated next-generation sequencing against single-gene testing or sequential molecular testing, although the tested genes, panel sizes, comparator strategies, and treatment pathways varied substantially across studies. Epidermal growth factor receptor and anaplastic lymphoma kinase were the most commonly included biomarkers. Overall, most studies suggested that next-generation sequencing was cost-effective compared with conventional testing strategies, but several studies from Asian settings reported unfavorable cost-effectiveness results. Key drivers of model results included treatment costs, time horizon, testing strategy, prevalence of actionable alterations, and turnaround time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current evidence suggests that NGS-guided strategies may improve health outcomes in NSCLC, but their economic value remains highly context-dependent. Cost-effectiveness is influenced not only by testing strategies, but also by the availability, accessibility, and cost of matched targeted therapies, as well as turnaround time and other real-world implementation factors. Future evaluations should therefore assess NGS within the broader molecular testing\u2013treatment pathway and better reflect real-world clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1896681","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:26:24Z","timestamp":1788841584000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic evaluations of next-generation sequencing for targeted therapy in non-small cell lung cancer: a systematic review"],"prefix":"10.3389","volume":"14","author":[{"given":"Zexiang","family":"Dai","sequence":"first","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Ye","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhou","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tian","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e260017","DOI":"10.6004\/jnccn.2026.0017","article-title":"Non-small cell lung cancer, version 4.2026, NCCN clinical practice guidelines in oncology","volume":"24","author":"Riely","year":"2026","journal-title":"J Natl Compr Cancer Netw"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e85245","DOI":"10.1371\/journal.pone.0085245","article-title":"Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations","volume":"9","author":"Liang","year":"2014","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/jama.2018.10096","article-title":"Broad-based molecular testing for lung cancer: precisely the time for precision","volume":"320","author":"Bunn","year":"2018","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3390\/diagnostics15050631","article-title":"Current biomarkers in non-small cell lung cancer\u2014the molecular pathologist\u2019s perspective","volume":"15","author":"Steinestel","year":"2025","journal-title":"Diagnostics"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"103561","DOI":"10.1016\/j.critrevonc.2021.103561","article-title":"The storm of NGS in NSCLC diagnostic-therapeutic pathway: how to sun the real clinical practice","volume":"169","author":"De Maglio","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jtho.2017.12.001","article-title":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology","volume":"13","author":"Lindeman","year":"2018","journal-title":"J Thorac Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing for patients with advanced cancer in 2024: a report from the ESMO precision medicine working group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.jval.2024.04.023","article-title":"Assessing the cost-effectiveness of next-generation sequencing as a biomarker testing approach in oncology and policy implications: a literature review","volume":"27","author":"Mirza","year":"2024","journal-title":"Value Health"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/14737167.2024.2388814","article-title":"Next-generation sequencing in oncology: challenges in economic evaluations","volume":"24","author":"Ehman","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.lungcan.2016.05.024","article-title":"Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: an early decision analytic model of multiplex targeted sequencing","volume":"107","author":"Doble","year":"2017","journal-title":"Lung Cancer"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e37867","DOI":"10.1016\/j.heliyon.2024.e37867","article-title":"Cost-effectiveness of multigene sequencing test and treatment for metastatic non-small cell lung cancer: a unique setting in the initial adoption phase in Japan allowing testing only after standard treatment","volume":"10","author":"Shiraiwa","year":"2024","journal-title":"Heliyon"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e2200201","DOI":"10.1200\/PO.22.00201","article-title":"Cost-effectiveness of parallel versus sequential testing of genetic aberrations for stage IV non-small-cell lung cancer in the Netherlands","volume":"6","author":"Wolff","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e2200294","DOI":"10.1200\/PO.22.00294","article-title":"Modeling costs and life-years gained by population-wide next-generation sequencing or single-gene testing in nonsquamous non-small-cell lung cancer in the United States","volume":"7","author":"Lemmon","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e0205827","DOI":"10.1371\/journal.pone.0205827","article-title":"Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China","volume":"13","author":"Lu","year":"2018","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/14737167.2022.2078310","article-title":"Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective","volume":"22","author":"de Alava","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.27030\/j.cnki.23-1042\/f.2023.10.014","article-title":"Economic evaluation of next-generation sequencing for mutation detection in non-small cell lung cancer","volume":"42","author":"Fu","year":"2023","journal-title":"Chin Health Econ"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"375","DOI":"10.31662\/jmaj.2023-0206","article-title":"Cost-effectiveness analysis of the Oncomine dx target test MultiCDx system using next-generation sequencing and single-gene test in advanced and recurrent nonsquamous non-small-cell lung cancer","volume":"7","author":"Kohara","year":"2024","journal-title":"JMA J"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.vhri.2023.08.006","article-title":"Cost-effectiveness of comprehensive genomic profiling in patients with non-small cell lung cancer for the Colombian health system","volume":"39","author":"Gamboa","year":"2024","journal-title":"Value Health Reg Issues"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"107970","DOI":"10.1016\/j.lungcan.2024.107970","article-title":"Cost-effectiveness of next-generation sequencing for advanced EGFR\/ALK-negative non-small cell lung cancer","volume":"197","author":"Kang","year":"2024","journal-title":"Lung Cancer"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1080\/13696998.2024.2413289","article-title":"Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne liquid CDx: a cost-effectiveness analysis","volume":"27","author":"Isla","year":"2024","journal-title":"J Med Econ"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s40273-024-01462-z","article-title":"Cost effectiveness of exclusionary EGFR testing for Taiwanese patients newly diagnosed with advanced lung adenocarcinoma","volume":"43","author":"Ou","year":"2025","journal-title":"PharmacoEconomics"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.19.00002","article-title":"Cost effectiveness of multigene panel sequencing for patients with advanced non-small-cell lung cancer","volume":"3","author":"Steuten","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1186\/s12885-021-08407-1","article-title":"Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario","volume":"21","author":"Nadal","year":"2021","journal-title":"BMC Cancer"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.jmoldx.2022.04.010","article-title":"Diagnostic value and cost-effectiveness of next-generation sequencing-based testing for treatment of patients with advanced\/metastatic non-squamous non-small-cell lung cancer in the United States","volume":"24","author":"Zou","year":"2022","journal-title":"J Mol Diagn"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"649","DOI":"10.18553\/jmcp.2024.30.7.649","article-title":"Cost-effectiveness of large-panel next-generation sequencing in guiding first-line treatment decisions for patients with nonsquamous advanced non-small cell lung cancer","volume":"30","author":"Abbass","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40258-025-00950-3","article-title":"Cost-utility analysis of genomic profiling in directing targeted therapy in advanced NSCLC in Thailand","volume":"23","author":"Turongkaravee","year":"2025","journal-title":"Appl Health Econ Health Policy"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e2200546","DOI":"10.1200\/PO.22.00546","article-title":"Cost-effectiveness of next-generation sequencing versus single-gene testing for the molecular diagnosis of patients with metastatic non-small-cell lung cancer from the perspective of Spanish reference centers","volume":"7","author":"Arriola","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13073-022-01041-x","article-title":"Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology","volume":"14","author":"Adib","year":"2022","journal-title":"Genome Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3390\/ijms22020612","article-title":"Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer","volume":"22","author":"Fois","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing for patients with metastatic cancers: a report from the ESMO precision medicine working group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/0284186X.2022.2098053","article-title":"Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer \u2013 the MetAction precision medicine study","volume":"61","author":"Ree","year":"2022","journal-title":"Acta Oncol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3892\/br.2022.1516","article-title":"Therapeutic impact and routine application of next-generation sequencing: a single institute study","volume":"16","author":"Hern\u00e1ndez-Pacheco Acosta","year":"2022","journal-title":"Biomed Rep"},{"key":"ref39","volume-title":"Libro Blanco de la Anatom\u00eda Patol\u00f3gica en Espa\u00f1a 2025: Recomendaciones de los Grupos de Trabajo para el Diagn\u00f3stico Anatomopatol\u00f3gico","author":"Torres Nieto","year":"2025"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e2400092","DOI":"10.1200\/PO.24.00092","article-title":"Clinical utility of tumor next-generation sequencing panel testing to inform treatment decisions for patients with advanced solid tumors in a tertiary care center","volume":"8","author":"Bogdan","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e2519963","DOI":"10.1001\/jamanetworkopen.2025.19963","article-title":"Biomarker testing approaches, treatment selection, and cost of care among adults with advanced cancer","volume":"8","author":"DaCosta Byfield","year":"2025","journal-title":"JAMA Netw Open"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e13619","DOI":"10.1200\/JCO.2024.42.16_suppl.e13619","article-title":"Changes in non-small cell lung cancer next-generation sequencing rates after electronic health record integration using large-scale, multi-institutional, real-world data","volume":"42","author":"Matrana","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e2200715","DOI":"10.1200\/PO.22.00715","article-title":"Comprehensive review on the clinical impact of next-generation sequencing tests for the management of advanced cancer","volume":"7","author":"Gibbs","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"97","DOI":"10.12019\/j.issn.1671-5144.202401019","article-title":"Current situation investigation of clinical diagnosis and treatment of non-small cell lung cancer with MET alterations in China","volume":"24","author":"Gan","year":"2024","journal-title":"Evid Based Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.cllc.2025.11.017","article-title":"A United States-based real-world study on biomarker testing and rebiopsy rates among patients with non-small cell lung cancer across lines of therapy","volume":"27","author":"Aggarwal","year":"2026","journal-title":"Clin Lung Cancer"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"178","DOI":"10.12019\/j.issn.1671-5144.202404009","article-title":"Research progress of the drug resistance mechanism of the third-generation ALK inhibitor lorlatinib in NSCLC","volume":"24","author":"Tian","year":"2024","journal-title":"J Evid Based Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41571-025-01085-z","article-title":"Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC\u2014mechanisms and evolving treatment approaches","volume":"23","author":"Zhao","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2174\/0113894501409916251103161912","article-title":"MET exon 14 skipping mutation in NSCLC: from genomic discovery to biomarker-guided therapeutic innovation","volume":"27","author":"Huang","year":"2026","journal-title":"Curr Drug Targets"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1896681\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:26:27Z","timestamp":1788841587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1896681\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":48,"alternative-id":["10.3389\/fpubh.2026.1896681"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1896681","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1896681"}}